Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4713 - Multiple Myeloma Metal Levels and Proteasome Activity

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cancer Biology

Tumour Site

Multiple Myeloma

Presenters

Kai Uwe Stumpf

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

K.U. Stumpf1, H. Einsele2, T. Nekova3

Author affiliations

  • 1 Biocomposition, Institute of Mineral Analysis, 97084 - Würzburg/DE
  • 2 Medical Policlinic Ii, University Hospital Wuerzburg, 97080 - Würzburg/DE
  • 3 Hematology, University Hospital Wuerzburg, 97080 - Würzburg/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4713

Background

The biologically active metal-based compounds are of interest in both prevention and treatment of cancer. Metal-containing complexes are essential for the normal biochemical processes, and due to their reactivity, imbalance in the metal concentration is linked to the development of diverse malignancy. Several proteasome inhibitors contain metal complexes. Bortezomib (a boron complex) is the first successfully used therapeutic proteasome inhibitor in multiple myeloma (MM). However, major clinical limitations of the drug are the severe side effects caused by the inhibition of proteasomal and non-proteasomal activity in normal cells. Here we analyze the associations between individual metals and proteasome activity.

Methods

The study was performed on MM cell lines MM.1S and L363. Chymotrypsin–like (CT-like) proteasome activity is the primary measure of the degradation potential of the proteasome. In order to determine how metals are linked to proteasome activity, we expose MM cells to bortezomib or 5-amino-8-hydroxyquinoline dihydrochloride (5AHQ) proteasome inhibitors. The CT-like activities of β5 and β5i subunit were measured and evaluated based on a cumulative inhibition of β5 and β5i CT-like sites. Metal content analysis of MM.1S and L363 cells was performed by total reflection X-ray fluorescence spectrometer.

Results

The metal content analysis demonstrated rigorous imbalances for calcium, phosphorus and potassium, moderate to no imbalances for iron and zinc accompanied by 65% MM.1S (54% L363) reduction of CT-like activity under bortezomib. However, under 5AHQ treatment, a decrease in the concentration of phosphorus and potassium was accompanied by minor to no change of iron and zinc levels and an increase of calcium. As metals may positively correlate or be antagonistic to one another, we evaluated the correlations between metals and proteasome activity.

Conclusions

Overall, our analysis suggests that the modulation of metal interactions specific to the proteasome activity is a strategy worth exploring to improve the efficacy of proteasome inhibition therapies.

Clinical trial identification

Legal entity responsible for the study

AG Hematology.

Funding

Wilhelm Sander Foundation.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.